Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05653492
PHASE2

Safety, Feasibility, and Tolerability of Sulforaphane in Children with Chronic Kidney Disease

Sponsor: University of Rochester

View on ClinicalTrials.gov

Summary

This purpose of this study is to investigate potential new therapeutics in pediatric chronic kidney disease (CKD). The specific aims are to identify safe dosing and tolerability of sulforaphane (SFN) supplementation in children with moderate and advanced CKD. Secondary objectives will include preliminary exploration of changes in oxidative and inflammatory biomarkers in response to SFN supplementation in this population.

Official title: Safety, Feasibility, and Tolerability of Sulforaphane in Children with CKD

Key Details

Gender

All

Age Range

1 Year - 17 Years

Study Type

INTERVENTIONAL

Enrollment

12

Start Date

2023-05-15

Completion Date

2025-12-31

Last Updated

2024-09-19

Healthy Volunteers

No

Interventions

DRUG

Sulforaphane

Dosing study one to four 30 mg/d tablets depending on weight

Locations (1)

University of Rochester Medical Center

Rochester, New York, United States